QCOR Questcor Pharmaceutical Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QCOR Questcor Pharmaceutical

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	9/20/2012 2:19:56 AM
	of 107

Questcor to Conduct Conference Call to Discuss Reimbursement Process ANAHEIM, Calif., Sept. 19, 2012 /PRNewswire via COMTEX/ -- Questcor Pharmaceuticals, Inc. (QCOR) today announced that it will conduct a conference call to discuss the reimbursement process for H.P. Acthar Gel (repository corticotrophin injection) prescriptions. The call will take place on Thursday, September 20, 2012 at 11 a.m. ET, 8 a.m. PT. The call can be accessed in the following ways: By webcast: At Questcor's investor relations website: ir.questcor.com. By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-941-9205. For participants outside the U.S., the dial-in number is 480-629-9771. By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call. The dial-in number for U.S. participants is 800-406-7325. For participants outside the U.S., the replay dial-in number is 303-590-3030. The replay access code for all callers is 4566307#.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next